Atraverse Medical, a San Diego-based medical device company, recently announced the FDA clearance of its HOTWIRE radiofrequency (RF) guidewire. This innovative device allows for zero exchange left-heart access while also serving as a rail for catheter-based therapy systems. The company also revealed that its seed round was oversubscribed, raising $12.5 million in funding.
These milestones represent a significant advancement in commercializing Atraverse Medical’s leading left-heart access technology. The funding includes contributions from prominent physicians, venture investors, and successful entrepreneurs in the medtech industry. This financial support will accelerate the company’s research and development efforts as well as its early commercialization initiatives.
The HOTWIRE system, developed by Atraverse Co-Founders Dr. Steven Mickelsen and Eric Sauter, signifies a new approach to left-heart access. With its universal sheath compatibility and optimized RF technology, the HOTWIRE aims to enhance patient outcomes and streamline procedural workflows.
Dr. Mickelsen, a cardiac electrophysiology physician at Scripps Hospital in Jolla, CA, highlighted the importance of the FDA clearance for the HOTWIRE in advancing medical innovation and improving procedures requiring transseptal access. Dr. Devi Nair, Director of Cardiac Electrophysiology and Research at St
